Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agents.

International journal of hematology - 1 Feb 2021

Sato Shuku, Kamata Wataru, Okada Satomi, Tamai Yotaro

Abstract excerpt

Translocation t(4;14) is an independent prognostic factor for adverse outcome in multiple myeloma (MM). However, reports concerning the therapeutic effects of novel drugs on t(4;14) MM are few. We retrospectively investigated the clinical and prognostic significance of symptomatic MM cases with t(4;14) treated with novel therapies. Ninety-three patients (IgG, 56; IgA, 23; BjP, 14) newly diagnosed with MM were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromosomes, Human, Pair 14
Share to Chromosomes, Human, Pair 4

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Disease Management

Share to Kaplan-Meier Estimate

Share to Multiple Myeloma

Share to Proportional Hazards Models

Share to Translocation, Genetic

Source

Identifiers

PMID: 32949373
DOI: 10.1007/s12185-020-03005-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agents.PMID 32949373Read ↗

Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesionsSemantic proximity Read ↗

Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocationSemantic proximity Read ↗

Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?Semantic proximity Read ↗

Clinical implications of cytogenetic and molecular aberrations in multiple myelomaSemantic proximity Read ↗

Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment responseSemantic proximity Read ↗

The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategiesSemantic proximity Read ↗

Many Multiple Myelomas: Making More of the Molecular MayhemSemantic proximity Read ↗

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.Semantic proximity Read ↗

Clinical and biologic implications of recurrent genomic aberrations in myelomaSemantic proximity Read ↗

Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysisSemantic proximity Read ↗

The biology of multiple myeloma.Semantic proximity Read ↗

Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging SystemSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.